Effect of Cellular-Based Artificial Antigen Presenting Cells Expressing ICOSL, in T-cell Subtypes Differentiation and Activation

Mehdi Talebi ^1,2 , Hojjatollah Nozad Charoudeh ³, Ali Akbar Movassaghpour Akbari ⁴, Behzad Baradaran ², Tohid Kazemi ² *

Cited by CrossRef: 3

1- Qiao S, Xie Y, Li H, Zhang R, Wu Y, Liu X, Zhang S. Cytokines/chemokines and soluble immune checkpoint molecules in anti-GABAB receptor encephalitis. Multiple Sclerosis and Related Disorders. 2022;68:104234 [Crossref]

2- Mateus D, Sebastião A, Frasco M, Carrascal M, Falcão A, Gomes C, Neves B, Sales M, Cruz M. Artificial Dendritic Cells: A New Era of Promising Antitumor Immunotherapy. Small. 2023;19(46) [Crossref]

3- Syed Altaf R, Mohan A, Palani N, Mendonce K, Monisha P, Rajadesingu S. A review of innovative design strategies: Artificial antigen presenting cells in cancer immunotherapy. International Journal of Pharmaceutics. 2025;669:125053 [Crossref]

4- López-Cantillo G, Urueña C, Camacho B, Ramírez-Segura C. CAR-T Cell Performance: How to Improve Their Persistence?. Front Immunol. 2022;13 [Crossref]